Abstract
In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Randomized clinical studies have demonstrated that intravenous thrombolysis with tissue plasminogen activator improves functional outcomes. Recently the time window for intravenous thrombolysis has been extended from 3 to 4.5 hours after stroke onset, which will allow more stroke patients to benefit from this treatment. Currently several studies are investigating how to improve recanalization rates of thrombolytic therapy. In this review several aspects of intravenous and intra-arterial thrombolysis are discussed.
Current Topics in Medicinal Chemistry
Title: Thrombolysis for Acute Ischemic Stroke
Volume: 9 Issue: 14
Author(s): M. Uyttenboogaart, J. De Keyser and G. J. Luijckx
Affiliation:
Abstract: In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Randomized clinical studies have demonstrated that intravenous thrombolysis with tissue plasminogen activator improves functional outcomes. Recently the time window for intravenous thrombolysis has been extended from 3 to 4.5 hours after stroke onset, which will allow more stroke patients to benefit from this treatment. Currently several studies are investigating how to improve recanalization rates of thrombolytic therapy. In this review several aspects of intravenous and intra-arterial thrombolysis are discussed.
Export Options
About this article
Cite this article as:
Uyttenboogaart M., De Keyser J. and Luijckx J. G., Thrombolysis for Acute Ischemic Stroke, Current Topics in Medicinal Chemistry 2009; 9 (14) . https://dx.doi.org/10.2174/156802609789869655
DOI https://dx.doi.org/10.2174/156802609789869655 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oral Disintegrating Tablets – An Updated Patent Perspective
Recent Patents on Drug Delivery & Formulation Physiological and Pharmacological Regulation of Hepatic 3-Hydroxy-3- Methylglutaryl Coenzyme A Reductase
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery The Effects of Direct Renin Inhibitor, Aliskiren, on Arterial Hypertension, Chronic Kidney Disease and Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Approaches to the Diagnosis of Classical form of Congenital Adrenal Hyperplasia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Graphical Abstracts
Current Diabetes Reviews Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology Antipsychotic Polypharmacy
Current Pharmaceutical Design Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies Editorial (Thematic Issue: Cardio-Metabolic Complications: Current Perspective and Future Developments)
Current Pharmaceutical Design Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice
Current Diabetes Reviews The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Meet the Editorial Board
Current Pharmaceutical Design Transcription Factors as Molecular Targets: Molecular Mechanisms of Decoy ODN and their Design
Current Drug Targets Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT<sab>2</sab> Receptor
Current Pharmaceutical Design